StockNews.AI
PLSE
StockNews.AI
218 days

Pulse Biosciences' Nanosecond PFA Technology to be Featured in Multiple Presentations at the AF Symposium

1. PLSE's nsPFA technology featured at the 30th Annual AF Symposium. 2. Renowned physicians to highlight clinical benefits of nsPFA 360° Catheter. 3. The presentation may boost credibility and visibility for the product. 4. Initiating U.S. IDE pivotal clinical study planned for mid-2025. 5. Positive feedback from the board reflects confidence in product development.

5m saved
Insight
Article

FAQ

Why Bullish?

The product's presentation at a major symposium elevates PLSE's market presence, akin to previous medical tech showcases leading to stock gains.

How important is it?

The article discusses significant developments in PLSE's technology and market strategy, influencing investor sentiment.

Why Long Term?

Increased visibility may enhance sales over time as clinical studies progress, similar to tech adoption cycles.

Related Companies

ABTMDT
MIAMI--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced that its nsPFA technology will be featured in a late-breaking science session and a live case transmission featuring the nsPFA 360° catheter mapped with the Abbott Ensite X 3D Mapping System at the 30th Annual AF Symposium 2025 meeting, being held January 16-18 in Boston, Massachusetts. “Since joining the Company’s Board last year I have seen the team make remarkable strides on the product development and clinical evidence with the proprietary nsPFA 360° Cardiac Catheter device. Having two renowned physicians showcase the clinical benefits of the differentiated mechanism of action and device at this vital AF scientific meeting is a strong testament to the team’s progress and the unique role of nsPFA,” said Paul LaViolette, Co-Chairman of Pulse Biosciences’ Board of Directors. “Pulse Biosciences will continue to advance its nsPFA technology within the clinical community as it drives towards initiating a U.S. IDE pivotal clinical study for the catheter in the middle of 2025.” Key Nanosecond PFA Scientific Programming Friday, January 17th 5:30-7:00pm, Vivek Reddy, MD – Late Breaking Clinical Science Session Title: Pulsed Field Ablation Using a Compliant Circular Catheter Delivering Nanosecond Pulses to Treat Atrial Fibrillation Review of the first 30 patients treated in a feasibility study with the nsPFA 360° Cardiac Catheter at Na Homolce Hospital by Drs. Vivek Reddy and Petr Neuzil Saturday, January 18th 7:30-9:30am, Petr Neuzil, MD, PhD (Homolka Hospital, Prague, Czech Republic) – Live Case Transmission Title: Nanosecond Pulsed Field Ablation for Atrial Fibrillation Live case broadcast from Na Homolce Hospital in Prague, CZ. The live case will highlight the nsPFA 360° Cardiac Catheter workflow efficiency for pulmonary vein isolation, and 3D mapping and navigation with the Abbott Ensite X system as part of a 3D navigation workflow. About Pulse Biosciences® Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the potential to improve the quality of life for patients. The Company’s proprietary CellFX® nsPFA™ technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The Company is actively pursuing the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers. Pulse Biosciences is now headquartered in Miami, Florida and maintains its office in Hayward, California. Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS, nsPFA, CellFX nsPFA and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries.

Related News